# High-grade serous ovarian carcinoma (HGSOC)

Source: https://onco.cc/terms/hgsoc/  
OnCo record `hgsoc` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

High-grade serous ovarian carcinoma is the most common type of ovarian cancer and the one most often found late; it actually starts in the fallopian tube and almost always has a broken TP53 gene, and it is the type PARP inhibitors were built for.

## Summary

The type behind about 70% of ovarian cancer deaths, and the one where maintenance therapy has changed the most. Near-universal TP53 mutation, ~50% homologous recombination deficiency (including ~20% BRCA1/2), extensive copy-number instability, few recurrent targetable mutations. Arises from serous tubal intraepithelial carcinoma, which is why opportunistic salpingectomy prevents it. PARP inhibitors, platinum, and FRα ADCs are the main therapeutic levers.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/High-grade_serous_carcinoma
- Wikipedia: https://en.wikipedia.org/wiki/High-grade_serous_carcinoma

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [TP53](https://onco.cc/targets/tp53/)
- terms: [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/)
- technologies: [Risk-reducing and opportunistic salpingectomy](https://onco.cc/technologies/risk-reducing-salpingectomy/)
- people: [Gilda Radner](https://onco.cc/people/gilda-radner/)
- collections: [Ovarian Cancer Research Alliance (OCRA)](https://onco.cc/collections/ovarian-cancer-research-alliance/)

---
JSON: https://onco.cc/api/v1/entities/hgsoc.json